Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGENERATE-COBRA: Autologous Bone Marrow Cells in Refractory Angina
NCT05711849Phase 2Recruiting
- Sponsor
- Barts Health NHS Trust
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of autologous bone marrow-derived mononuclear cell in Angina Pectoris (AP) (2 arms), sponsored by Barts Health NHS Trust. Primary endpoint: Canadian Cardiovascular Society Angina Score at 6 months. Started Mar 2024; status: recruiting.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT05711849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711849.